Intestinal Research

Reviews

IBD

Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities: Kanishk Aggarwal, Bhupinder Singh, Abhishek Goel, Durgesh Kumar Agrawal, Sourav Bansal, Sai Gautham Kanagala, Fnu Anamika, Aachal Gupta, Rohit Jain; Intest Res 2024;22(4):414-427. Published online June 5, 2024; DOI: https://doi.org/10.5217/ir.2024.00001

Nonalcoholic fatty liver disease (NAFLD) has been shown to be linked to inflammatory bowel disease (IBD) due to established risk factors such as obesity, age, and type 2 diabetes in numerous studies. However, alternative research suggests that factors related to IBD, such as disease activity, duration, and drug-induced toxicity, can contribute to NAFLD. Recent research findings suggest IBD relapses are correlated with dysbiosis, mucosal damage, and an increase in cytokines. In contrast, remission periods are characterized by reduced metabolic risk factors. There is a dichotomy evident in the associations between NAFLD and IBD during relapses and remissions. This warrants a nuanced understanding of the diverse influences on disease manifestation and progression. It is possible to provide a holistic approach to care for patients with IBD by emphasizing the interdependence between metabolic and inflammatory disorders.

Citations

Citations to this article as recorded by

Elucidating the association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a focus on systemic inflammation
Sihyun Kim, Jong Pil Im
Intestinal Research.2025; 23(1): 3. CrossRef

6,666 View
182 Download
2 Web of Science
1 Crossref

IBD

Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease: Samridhi Lakhanpal, Kanishk Aggarwal, Harmanjit Kaur, Kunal Kanwar, Vasu Gupta, Jill Bhavsar, Rohit Jain; Intest Res 2025;23(1):23-36. Published online May 7, 2024; DOI: https://doi.org/10.5217/ir.2023.00104

Abstract PDF PubReader ePub

Inflammatory bowel disease (IBD) is a spectrum of diseases characterized by the interplay of the aberrant immune system, genetic factors, environmental factors, and intestinal microbiota, resulting in relapsing inflammation of the gastrointestinal tract. Underlying pro-inflammatory state and immune dysregulation act as a catalyst for increasing the likelihood of developing extraintestinal manifestations, including cardiovascular diseases (CVD) like atherosclerosis, pericarditis, myocarditis, venous and arterial thromboembolism, arrhythmias, despite a lower prevalence of classic CVD risk factors, like high body mass index or dyslipidemia compared to the general population. Chronic inflammation damages endothelium resulting in the recruitment of inflammatory cells, which induce cytotoxicity, lipoprotein oxidation, and matrix degradation, which increases the risk of atherosclerosis. Additionally, intestinal dysbiosis disrupts the intestinal mucosal barrier, releasing endotoxins and lipopolysaccharides into circulation, further exaggerating the atherosclerotic process. Abnormal collagen metabolism and alteration of nitric oxide-mediated vasodilation lead to blood pressure dysregulation in patients with IBD. Therefore, it is essential to make lifestyle modifications like smoking cessation, dietary changes, and increasing physical activity with adherence to medication to mitigate the risk of developing CVD in patients with IBD. This article reviews the potential links between IBD and the increased risk of CVD in such individuals.

Citations

Citations to this article as recorded by

Association Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses
Yanfeng Lin, Xiaohui Qin, Haiyan Zhang, Jinke Huang, Xingshun Qi
Canadian Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Metabolic Disorders and Inflammatory Bowel Diseases
Hye Kyung Hyun, Jae Hee Cheon
Gut and Liver.2025; 19(3): 307. CrossRef
Carnitine: Its Crucial Role in Metabolic Health and Cardiovascular Function
Fremita Fredrick, Kanishk Aggarwal, Anish Kumar Reddy Meda, Fnu Anamika, Amishi Singla, Pranjal Jain, Rohit Jain
Journal of Dietary Supplements.2025; 22(5): 664. CrossRef
The gut-heart axis: a correlation between Paneth cells’ dysfunction, microbiome dysbiosis, and cardiovascular diseases
Aysa Rezabakhsh, Solomon Habtemariam, Rezayat Parvizi, Anne Meddahi-Pellé, Violeta Rodriguez Ruiz, Graciela Pavon-Djavid, Abolfazl Barzgari
Cell Communication and Signaling.2025;[Epub] CrossRef
Study design of ‘PASIBO’ - co-creation and development of a physical activity intervention to patients with inflammatory bowel disease
Tanja Thomsen, Marie Villumsen, Anja Poulsen, Anders B. G. Hansen, Bente A. Esbensen, Tine Jess, Mette Aadahl
BMC Health Services Research.2025;[Epub] CrossRef
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks
Oscar Noble, Dayoung Jeon, Megan Lewis, Christopher Fan, Khurram Nasir, Bincy P. Abraham
Current Atherosclerosis Reports.2025;[Epub] CrossRef
Cardiovascular Complications Are Increased in Inflammatory Bowel Disease: A Path Toward Achievement of a Personalized Risk Estimation
Vito Annese, Maria Laura Annunziata, Guglielmo Albertini Petroni, Emanuele Orlando, Sofia Cinque, Marzio Parisi, Paolo Biamonte, Giuseppe Dell’Anna, Anna Latiano, Serenella Castelvecchio
Journal of Personalized Medicine.2025; 15(9): 418. CrossRef
Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease
Dae Sung Kim, Won Moon
The Korean Journal of Internal Medicine.2025; 40(6): 866. CrossRef
Clinical Outcomes of Venous Thromboembolism in Patients with Ankylosing Spondylitis vs. Other Immune-mediated Inflammatory Diseases: Insights from the RIETE Registry
Romain Chopard, Gregory Piazza, Laurent Bertoletti, Nicolas Meneveau, Leticia Guirado, José Antonio Porras, Francisco Rivera-Cívico, José Felipe Varona Arche, Manuel Monreal, Clément Prati
Thrombosis and Haemostasis.2025;[Epub] CrossRef

9,916 View
289 Download
10 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search